StockData

MBX Biosciences vs Viking Therapeutics

MBX and VKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MBX and VKTX compare

Viking Therapeutics is the larger company, worth 1.3 times as much as MBX Biosciences ($3.4B against $2.6B).

MBX Biosciences scores higher on the StockData Score (7 against 5 for Viking Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMBXVKTX
Size and price
Market cap$2.6B$3.4B
Share price$53.12$26.80
Change, 1 year121%−31.3%
Change, 5 years–398%
Beta (5Y)2.071.24
Employees6353
StockData Score
Total score7 (better)5
Valuation score00
Growth score00
Performance score1 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/B5.4× (better)5.8×
FCF yield−3.9%–
Profitability
Return on equity−33.7% (better)−96.4%
Financial health
Debt / equity0.000.00
Current ratio19.58 (better)7.27
Altman Z-score54.56 (better)2.23
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions115%59.4%
Held by insiders57.3%2.7%
Insider net buying, 12 months−$2.5M (better)−$18.2M
Short interest, % of float20.8%19.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.